China expresses opposition against US tariff decision
(MENAFN) China strongly opposed the recent US decision to impose a 10 percent tariff on Chinese exports, vowing to take countermeasures to protect its interests. A spokesperson from the Foreign Ministry emphasized that trade and tariff wars yield no winners, asserting that the US's unilateral tariff hikes are a severe violation of WTO regulations. The statement added that such measures will not resolve domestic issues in the US and will ultimately be detrimental to both countries and the global economy.
Addressing the issue of fentanyl, the statement highlighted that China has provided support to the US in its efforts to combat the crisis based on principles of humanity and goodwill. In response to a request from Washington, China classified fentanyl-related substances as a controlled category in 2019, becoming the first country in the world to take such action. The statement underscored that China has engaged in extensive counternarcotics cooperation with the US.
China urged the US to approach its fentanyl crisis with objectivity and rationality rather than resorting to arbitrary tariff hikes as a means of pressure. The statement warned that additional tariffs would not be constructive and could negatively impact future collaboration between the two nations in combating drug-related issues.
A spokesperson from China's Commerce Ministry also voiced strong dissatisfaction and firm opposition to the US tariffs, reiterating that the move violates WTO rules. The statement stressed that unilateral tariff measures will not help the US resolve its challenges but will instead harm normal economic and trade relations between the two countries.
MENAFN02022025000045015839ID1109157407
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.